Holen Sie sich die Stockscreener-App
76.74
1.03%
0.78
Schlusskurs vom Vortag:
$75.96
Offen:
$76.35
24-Stunden-Volumen:
768.33K
Relative Volume:
0.53
Marktkapitalisierung:
$6.16B
Einnahmen:
$900.66M
Nettoeinkommen (Verlust:
$-453.20M
KGV:
-12.92
EPS:
-5.94
Netto-Cashflow:
$-274.19M
1W Leistung:
-2.32%
1M Leistung:
-2.24%
6M Leistung:
+56.13%
1J Leistung:
+67.26%
1-Tages-Spanne:
$75.02
$76.75
1-Wochen-Bereich:
$75.02
$78.67
52-Wochen-Spanne:
$35.95
$87.50
Ptc Therapeutics Inc Stock (PTCT) Company Profile
Firmenname
Ptc Therapeutics Inc
Sektor
Branche
Telefon
(908) 222-7000
Adresse
500 WARREN CORPORATE CENTER DRIVE, WARREN, NJ
Vergleichen Sie PTCT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PTCT
Ptc Therapeutics Inc
|
76.74 | 6.10B | 900.66M | -453.20M | -274.19M | -5.94 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.13 | 115.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.31 | 81.12B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.17 | 52.54B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
839.99 | 51.78B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.12 | 37.12B | 447.02M | -1.18B | -906.14M | -6.1812 |
Ptc Therapeutics Inc Stock (PTCT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-01 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-10-20 | Eingeleitet | Wells Fargo | Overweight |
| 2025-06-17 | Eingeleitet | Truist | Buy |
| 2025-05-09 | Hochstufung | BofA Securities | Neutral → Buy |
| 2025-05-07 | Hochstufung | Citigroup | Sell → Neutral |
| 2025-03-11 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2025-03-07 | Eingeleitet | Scotiabank | Sector Perform |
| 2024-12-13 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-03 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-10-10 | Fortgesetzt | Raymond James | Mkt Perform |
| 2024-09-04 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-08-26 | Fortgesetzt | UBS | Buy |
| 2024-05-20 | Hochstufung | Raymond James | Underperform → Mkt Perform |
| 2023-12-19 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2023-12-08 | Eingeleitet | Wells Fargo | Overweight |
| 2023-10-30 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2023-10-27 | Herabstufung | Citigroup | Neutral → Sell |
| 2023-10-06 | Herabstufung | Truist | Buy → Hold |
| 2023-09-18 | Herabstufung | Citigroup | Buy → Neutral |
| 2023-09-15 | Herabstufung | Raymond James | Outperform → Underperform |
| 2023-03-17 | Eingeleitet | SVB Securities | Market Perform |
| 2022-12-14 | Eingeleitet | Goldman | Sell |
| 2022-09-12 | Eingeleitet | Jefferies | Buy |
| 2022-09-09 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2022-09-01 | Eingeleitet | Citigroup | Buy |
| 2022-04-04 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2021-10-18 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Neutral |
| 2021-03-29 | Hochstufung | RBC Capital Mkts | Underperform → Sector Perform |
| 2021-02-12 | Herabstufung | BofA Securities | Buy → Neutral |
| 2021-01-05 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-11-30 | Herabstufung | RBC Capital Mkts | Sector Perform → Underperform |
| 2020-10-30 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-10-28 | Eingeleitet | UBS | Neutral |
| 2020-10-07 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2020-08-25 | Eingeleitet | Raymond James | Outperform |
| 2020-04-09 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-02-20 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-02-20 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-11-12 | Eingeleitet | SunTrust | Buy |
| 2019-05-13 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2019-04-11 | Eingeleitet | Bernstein | Outperform |
| 2018-10-03 | Hochstufung | BofA/Merrill | Underperform → Neutral |
| 2018-10-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-07-19 | Eingeleitet | Credit Suisse | Outperform |
| 2018-06-18 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2018-04-04 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2018-01-29 | Fortgesetzt | RBC Capital Mkts | Sector Perform |
| 2017-11-16 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2017-10-26 | Herabstufung | BofA/Merrill | Neutral → Underperform |
| 2017-10-09 | Herabstufung | JP Morgan | Neutral → Underweight |
Alle ansehen
Ptc Therapeutics Inc Aktie (PTCT) Neueste Nachrichten
PTC Therapeutics (NASDAQ:PTCT) Upgraded to Buy at Wall Street Zen - MarketBeat
Matthew Klein Sells 8,089 Shares of PTC Therapeutics (NASDAQ:PTCT) Stock - MarketBeat
Behavioral Patterns of PTCT and Institutional Flows - Stock Traders Daily
What's Going On With Royalty Pharma Stock Wednesday? - Benzinga
Duchenne Muscular Dystrophy (DMD) Therapeutics Market to Reach - openPR.com
Royalty Pharma Acquires Remaining Evrysdi Royalties From PTC Therapeutics - Nasdaq
Royalty Pharma Acquires Final Portion of Evrysdi Royalty from PTC Therapeutics for $240 Million - Quiver Quantitative
PTC Therapeutics Fully Monetizes Evrysdi Royalty Interest - TipRanks
PTC Therapeutics Signs Royalty Purchase Agreement Amendment With Royalty Pharma - TradingView — Track All Markets
PTC Therapeutics Swings to a Profit on $211 Million in Revenue — Is This Why a Major Fund Just Invested $32 Million? - AOL.com
Pacer Advisors Inc. Has $30.93 Million Stock Position in PTC Therapeutics, Inc. $PTCT - MarketBeat
Weekly Buzz: FDA OKs Roche's Lunsumio VELO; It's No For Tolbrutinib; BioMarin, SNY Open Wallets - RTTNews
PTC Therapeutics Earnings Notes - Trefis
PTC Therapeutics (NASDAQ:PTCT) Insider Eric Pauwels Sells 20,508 Shares of Stock - MarketBeat
PTC Therapeutics Executive Eric Pauwels Sells Over 20,000 Shares - TradingView — Track All Markets
Director Reeve Emma exercised 733 shares at a strike of $46.54 and sold $57,628 worth of shares (733 units at $78.62) (SEC Form 4) - Quantisnow
PTC Therapeutics Announces Approval of Sephience™ (sepiapterin) for the Treatment of Children and Adults Living with Phenylketonuria (PKU) in Japan - Sahm
Japan Sephience Approval Could Be A Game Changer For PTC Therapeutics’ (PTCT) Rare-Disease Strategy - Yahoo Finance
PTC Therapeutics (PTCT): Valuation Check After First Japan Approval Completes Global Sephience Launch - Yahoo Finance
(PTCT) Volatility Zones as Tactical Triggers - news.stocktradersdaily.com
PTC Therapeutics Announces Approval of Sephience™ (sepiapterin) - GuruFocus
PTC Therapeutics' Phenylketonuria Treatment Approved in Japan - marketscreener.com
PTC Therapeutics receives Japan approval for PKU treatment Sephience By Investing.com - Investing.com Nigeria
Voya Investment Management LLC Has $17.48 Million Position in PTC Therapeutics, Inc. $PTCT - MarketBeat
PTCT Gains Japanese Approval for Phenylketonuria Treatment - GuruFocus
PTC Therapeutics receives Japan approval for PKU treatment Sephience - Investing.com
PTC Therapeutics, Inc. $PTCT Shares Sold by Assenagon Asset Management S.A. - MarketBeat
PTC Therapeutics Shares Drop After FDA Rejects Vatiquinone Application - MSN
Assessing PTC Therapeutics (PTCT) Valuation After Health Canada’s Sephience Approval Expands PKU Market Potential - Sahm
EPS Watch: Why millennials buy PTC Therapeutics Inc. (BH3) stock2025 Winners & Losers & Short-Term Swing Trade Alerts - ulpravda.ru
PTC Therapeutics (PTCT) Gets a Buy from Wells Fargo - The Globe and Mail
Will PTC Therapeutics Inc. stock attract more institutional investors2025 Trading Volume Trends & Accurate Buy Signal Notifications - Улправда
Insider Sell Alert: Eric Pauwels Sells 43,492 Shares of PTC Ther - GuruFocus
Eric Pauwels Sells 3,202 Shares of PTC Therapeutics (NASDAQ:PTCT) Stock - MarketBeat
PTC Therapeutics Executive Eric Pauwels Sells Over $3 Million in Company Stock - TradingView — Track All Markets
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GuruFocus
Officer Pauwels Files To Sell 20,508 Of PTC Therapeutics Inc [PTCT] - TradingView — Track All Markets
Is PTC Therapeutics Inc. stock supported by innovation pipelineMarket Movement Recap & Free Weekly Chart Analysis and Trade Guides - Улправда
Is PTC Therapeutics Inc. (BH3) stock undervalued by metricsQuarterly Portfolio Report & Free Reliable Trade Execution Plans - Улправда
Why PTC Therapeutics Inc. stock remains resilient2025 Price Momentum & Daily Volume Surge Trade Alerts - DonanımHaber
Is PTC Therapeutics Inc. stock a defensive play in 2025Market Performance Summary & Low Drawdown Momentum Ideas - DonanımHaber
Aug Catalysts: Is PTC Therapeutics Inc. (BH3) stock undervalued by metrics2025 Investor Takeaways & Real-Time Volume Spike Alerts - ulpravda.ru
PTC Therapeutics (PTCT) director exercises stock option, now holds 155,266 shares - Stock Titan
Why hedge funds are buying PTC Therapeutics Inc. stockJuly 2025 Technicals & Fast Entry and Exit Trade Plans - Улправда
PTC Therapeutics to Present at the 44th Annual J.P. Morgan Healt - GuruFocus
PTC Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference - Nasdaq
Officer Pauwels Files To Sell 40,290 Of PTC Therapeutics Inc [PTCT] - TradingView — Track All Markets
PTC Therapeutics (PTCT) Is Down 9.5% After Broad S&P Additions And Insider Moves Has The Bull Case Changed? - Sahm
PTC Therapeutics Announces Health Canada Approval of Sephience™ (sepiapterin) for the Treatment of Children and Adults Living with Phenylketonuria (PKU) - Quantisnow
PTC Therapeutics, Inc. (NASDAQ:PTCT) Q1 2025 Earnings Call Transcript - MSN
Squarepoint Ops LLC Grows Stake in PTC Therapeutics, Inc. $PTCT - MarketBeat
Finanzdaten der Ptc Therapeutics Inc-Aktie (PTCT)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.57%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):